Watson files for generic Mucinex D
This article was originally published in The Tan Sheet
Executive Summary
The Corona, Calif.-based firm seeks to market generic extended-release guaifenesin pseudoephedrine HCl 600 mg/60 mg and 1200 mg/120 mg, equivalent to Reckitt Benckiser's Mucinex D and Maximum Strength Mucinex D expectorant and nasal decongestant. Watson said June 10 it appears to be the first to file an abbreviated new drug application for the product, meaning it would be entitled to 180 days of generic market exclusivity should it overcome Reckitt's patents. Reckitt filed suit against Watson June 5, as it did upon Watson's April filings to market generic Mucinex and Mucinex DM (1"The Tan Sheet" April 27, 2009, p. 10). Watson says Mucinex D products totaled about $62 million in U.S. sales for the 12 months ended March 31, based on IMS Health data
You may also be interested in...
Watson Files ANDA For Mucinex DM, Gets In Line For Generic Guaifenesin
Watson Pharmaceuticals appears to be the first firm to file an abbreviated new drug application with FDA to market a private label version of Reckitt Benckiser's Mucinex DM
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.